Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases

BACKGROUND: The anaplastic lymphoma kinase (ALK) mutation, also known as the diamond mutation in non–small-cell lung cancer (NSCLC), has been treated with tremendous success since it was first reported in 2007. Alectinib, a second generation ALK-Tyrosine kinase inhibitor (TKI), has been reported to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Shan, Sun, Huiying, Wu, Jianhua, Lu, Hao, Fang, Yisheng, Wang, Yuanyuan, Liao, Wangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356229/
https://www.ncbi.nlm.nih.gov/pubmed/35941871
http://dx.doi.org/10.3389/fonc.2022.916315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356229/
https://www.ncbi.nlm.nih.gov/pubmed/35941871
http://dx.doi.org/10.3389/fonc.2022.916315

Ejemplares similares